Activating mutations in members of the RAS oncogene family (KRAS, HRAS, and NRAS) have been found in a variety of human malignancies, suggesting a dominant role in carcinogenesis. In colon cancers, KRAS mutations are common and clearly contribute to malignant progression. The frequency of NRAS mutations and their relationship with clinical, pathologic, and molecular features remains uncertain. We developed and validated a Pyroseqencing assay to detect NRAS mutations at codons 12, 13, and 61. Using a collection of 225 colorectal cancers from 2 prospective cohort studies, we examined the relationship between NRAS mutations, clinical outcome, and other molecular features, including mutation of KRAS, BRAF, and PIK3CA, microsatellite instability, and the CpG island methylator phenotype. Finally, we examined whether NRAS mutation was associated with patient survival or prognosis. NRAS mutations were detected in 5 (2.2%) of the 225 colorectal cancers and tended to occur in left-sided cancers arising in women, but did not seem to be associated with any of the molecular features that were examined.
T he RAS proto-oncogenes (HRAS, KRAS, and NRAS) encode a family of GDP/GTP-regulated switches that convey extracellular signals to regulate the growth and survival properties of cells. 1 The 4 enzymes encoded by the 3 RAS genes are highly homologous to one another, sharing a high degree of identity over the first 90% of the proteins. The extreme carboxy-termini of the proteins constitute the hypervariable region, which diverges radically in primary sequence and undergoes posttranslational modification that confers important differences in trafficking and intracellular localization.
RAS family members are frequently found in their mutated, oncogenic forms in human tumors. Mutant RAS proteins are constitutively active, owing to reduced intrinsic GTPase activity and insensitivity to GTPaseactivating proteins. In total, activating mutations in the RAS genes occur in approximately 20% of all human cancers, mainly in codon 12, 13, or 61. 2, 3 Mutations in KRAS account for about 85% of all RAS mutations in human tumors, NRAS for about 15%, and HRAS for less than 1%. 4 Which particular RAS gene is mutated seems to be tumor specific; colonic, pancreatic, and lung cancers have high frequencies of KRAS mutations. For example, we reported that KRAS gene mutations were present in 277 (36%) of 772 colorectal cancers analyzed. 5, 6 NRAS mutations, by contrast, are common in myeloid leukemias and cutaneous melanomas. 7, 8 Nevertheless, the frequency of NRAS mutations in colorectal cancer remains unclear.
GTP-bound RAS transmits its signal through a variety of downstream ''effector'' pathways, for example, the RAF-MEK-ERK and PI3K-AKT cascades. Activating NRAS mutations occur in up to 30% of cutaneous melanoma cases and BRAF mutations also occur at a high frequency in these cancers. Recently, it has been reported that mutations in BRAF or NRAS are associated with decreased survival in patients with metastatic melanoma. 9,10 Interestingly, BRAF mutations are mutually exclusive with NRAS mutations in melanoma and with KRAS mutations in colorectal cancer. [11] [12] [13] [14] [15] [16] [17] By contrast, mutations in PIK3CA (which encodes the p110a catalytic subunit of PI3K) tend to coexist with KRAS mutations in colorectal cancer. 18, 19 The patterns of mutational cooccurrence suggest that each RAS effector plays a different role in tumor development. In this respect, understanding the genetic context in which NRAS mutations arise is important.
In this study, we used Pyrosequencing to identify NRAS mutations at codons 12, 13, and 61, the mutational hotspots for all of the RAS genes, in a set of 225 colorectal cancers. We examined the relationship between NRAS mutations and other molecular, pathologic, and clinical features, including mutations in KRAS, BRAF, and PIK3CA, microsatellite instability (MSI), CpG island methylator phenotype (CIMP) status, and patient survival.
MATERIALS AND METHODS

Tissue Specimens
Experimental samples were identified by searching the databases of 2 large prospective cohort studies: the Nurses' Health Study (N = 121,700 women followed since 1976) and the Health Professionals Follow-up Study (N = 51,500 men followed since 1986). 20 A subset of the cohort participants developed colorectal cancer during prospective follow-up. Earlier studies on the Nurses' Health Study and Health Professionals Follow-up Study have described baseline characteristics of cohort participants and incident colorectal cancer cases and confirmed that our colorectal cancers were a good representative of a population-based sample. 20, 21 We collected paraffinembedded tissue blocks from hospitals in which cohort participants with colorectal cancers had undergone resections of primary tumors. On the basis of availability of tissue materials and assay results, a total of 225 colorectal cancers were included in this study. Among our cohort studies, there was no significant difference in demographic features between cases with tissue available and those without available tissue. 22 Hematoxylin and eosin-stained tissue sections were examined by a pathologist (S.O.) unaware of clinical or other laboratory data. 23 The tumor grade was categorized as low (Z50% gland formation) versus high (<50% gland formation). The presence and extent of extracellular mucin and signet ring cells were recorded. Although many of the cases have been characterized earlier for the status of CIMP, MSI, KRAS, BRAF, and p53, 23 we have not examined NRAS mutations in our specimens. Informed consent was obtained from all patients. Tissue collection and analyses were approved by the Brigham and Women's Hospital and Harvard School of Public Health Institutional Review Boards.
Genomic DNA Extraction and Whole-genome Amplification
Genomic DNA was extracted from paraffin-embedded tumor tissue sections using QIAmp DNA Mini Kit (Qiagen, Valencia, CA). 24 Normal DNA was obtained from colonic tissue at resection margins. Whole-genome amplification (WGA) of genomic DNA was performed by polymerase chain reaction (PCR) using random 15-mer primers. 24, 25 Earlier studies showed that WGA did not significantly affect downstream genetic analysis. 26, 27 Pyrosequencing for NRAS The primers for PCR and Pyrosequencing were purchased from EpigenDx Inc. (EpigenDx, Worcester, MA), and PCR was conducted according to the protocol recommended by the manufacturer. Each PCR mix contained 3 pmol of forward primer, 0.3 pmol of reverse primer, 2.7 pmol of universal primer, 200 mmol each of dNTPs, 3.0 mmol MgCl 2 , 1 Â PCR buffer (Qiagen, Valencia, CA), 0.75 U of HotStar Taq polymerase (Qiagen), and 1 mL of template WGA product in a total volume of 30 mL. PCR conditions were as follows: initial denaturing at 951C for 15 minutes; 45 cycles of 951C for 30 seconds, 581C for 30 seconds, and 721C for 30 seconds; and final extension at 721C for 5 minutes. The PCR products (each 10 mL) were sequenced using the Pyrosequencing PSQ96 HS System (Qiagen) according to the manufacturer's instructions. The nucleotide dispensation orders were codon 12-ACT GAC TAC GAC T, codon 13-CAT GAC TAC TGA CTG, codon 61-ACG TCT AGC AGT. To increase sensitivity, we designed a different Pyrosequencing primer for codon 13: 5 0 -GTGGTGGTTGGAG CAGGTG-3 0 . The use of 3 sequencing primers served as a quality control measure, because mutations in codon 13 are detected by at least 2 primers. To confirm the results, we repeated PCR-Pyrosequencing, with laboratory staff unaware of the earlier results, using unique nucleotide dispensation orders and at a different facility (EpigenDx): codon 12 and 13-TCG ATG CTA GTG TGC AGC G, codon 61-CAT CGA TCA G.
Sanger Sequencing Analysis for NRAS
The mutational status of NRAS was confirmed by direct sequencing of PCR products generated using the following primer pairs: exon 2, 5 0 -ACGTTGGATGCA ACAGGTTCTTGCTGGTGT-3 0 (forward) and 5 0 -AC GTTGGATGGAGAGACAGGATCAGGTCAGC-3 0 (reverse); exon 3, 5 0 -ACGTTGGATGTGGTGAAACCTG TTTGTTGG-3 0 (forward) and 5 0 -ACGTTGGATGCC TTTCAGAGAAAATAATGCTCCT-3 0 (reverse). PCR was performed in a volume of 20 mL, containing 1 unit of Taq polymerase (Invitrogen, Carlsbad, CA), 4 nmol of dNTPs (Invitrogen, Carlsbad, CA), 10 pmol of forward and reverse primers, 40 24 BRAF codon 600, 28 and PIK3CA exons 9 and 20 were performed. 5 MSI status was determined using D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487. 29 MSI-high was defined as the presence of instability in Z30% of the markers, MSI-low as instability in 1% to 29% of the markers, and microsatellite stability (MSS) as the absence of instability. For 18q loss of heterozygosity (LOH) analysis using microsatellite markers (D18S55, D18S56, D18S67, and D18S487), LOH at each locus was defined as Z40% reduction of 1 of 2 allele peaks in tumor DNA relative to normal DNA. 30 Overall 18q LOH positivity was defined as the presence of any marker with LOH, and 18q LOH negativity as the presence of Z2 informative markers and the absence of LOH.
Real-time PCR to Measure CpG Island Methylation and Pyrosequencing to Measure LINE-1 Methylation
Bisulfite DNA treatment and real-time PCR (Methy Light) assays were validated and performed. 31 We quantified methylation at 8 CIMP-specific CpG islands [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1]. 23, 29 CIMP-high was defined as Z6/8 methylated promoters using the 8-marker CIMP panel, CIMP-low as 1 of 8 to 5 of 8 methylated promoters and CIMP-0 as 0 of 8 methylated promoters, according to the criteria established earlier. 23 We also quantified methylation at 8 other loci (CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14, and WRN). 6, 18 The percentage of methylated reference at a specific locus was calculated as described earlier. 31 The LINE-1 methylation level was measured by Pyrosequencing. 32 
Immunohistochemistry
We constructed tissue microarrays. 22 The methods of immunohistochemistry were described earlier as follows: cyclin D1, 33 b-catenin, 34 p21, p27, p53, 35 fatty acid synthase (FASN) and COX-2. 36 All immunohistochemically stained slides for each marker were interpreted by one of the investigators (p53, p21, p27, COX- 
Statistical Analysis
Fisher exact test was performed to assess associations between categorical data, using the SAS program (version 9.1; SAS Institute, Cary, NC). All P values were 2-sided, and statistical significance was set at Pr0.05. A correction of multiple hypothesis testing was not attempted because of a limited power.
RESULTS
NRAS Mutation in Colorectal Cancer
We used Pyrosequencing to determine the frequency of NRAS codons 12, 13, and 61 mutations in sporadic colorectal cancer. The normal amino acid at codons 12 and 13 of the NRAS gene is glycine (GGT) and the normal amino acid at codon 61 is glutamine (CAA). In this study of 225 colorectal cancers, 5 cases (2.2%) harbored NRAS-activating mutations (Fig. 1) . These mutations were confirmed by different nucleotide dispensation orders for Pyrosequencing and by Sanger sequencing. The activating mutations found in the NRAS gene were c.34G>A (p.G12S), c.35G>A (p.G12D), and c.35G>T (p.G12V) in codon 12 and c.181C>A (p.Q61K) in codon 61. No codon 13 mutations were detected. These NRAS mutations have been described in other cancers (the Sanger Institute COSMIC database; www.sanger.ac.uk/genetics/CGP/cosmic/).
NRAS Mutation and Clinical, Pathologic, Prognostic, and Molecular Features
We examined genetic and epigenetic features and the clinical outcome of 225 colorectal cancer cases according to NRAS mutation status ( Table 1) . A distribution of various molecular features detected in our colorectal cancers was essentially in agreement with earlier studies. 18, [37] [38] [39] [40] [41] Table 2 shows clinical, pathologic, and molecular features of colorectal cancers with NRAS mutations. NRAS mutations were mutually exclusive with mutations in BRAF, KRAS, and PIK3CA, although the sample size was limited. All of the cancers with NRAS mutations were located in the distal (left side) colon and 4 of 5 arose in female patients. Nevertheless, because of the low frequency of NRAS mutation, none of those relations was statistically significant. There was no apparent association between the NRAS mutations and any of the other clinical or pathologic features examined (Table  1) . Similarly, there was no significant association between NRAS mutation and any of the other tumoral markers in Table 1 , or to b-catenin, p53, p21, p27, cyclin D1, COX-2, and FASN (data not shown). In addition, no significant effect of NRAS mutation on patient survival was noted (data not shown).
DISCUSSION
We conducted this study to examine the frequency of NRAS mutation in relation to various genetic and epigenetic alterations in colorectal cancer. The RAS pathway plays an important role in the development of various cancers, [42] [43] [44] and frequent activating mutations in the KRAS oncogene have been identified in colorectal cancer. 24 Nevertheless, there are only a few reports on NRAS mutations in colorectal cancer and none of these studies correlated RAS mutations with other molecular events. 45, 46 We developed a Pyrosequencing assay to detect NRAS mutations because this methodology has been shown to be applicable to paraffin-embedded tumors and is more sensitive than Sanger dideoxy sequencing in KRAS mutation analysis. 24 We found that NRAS mutation in colorectal cancer was rare (2.2%). This observation is consistent with publicly available cancer genome sequencing data from the Sanger Institute COSMIC database (www.sanger.ac.uk/genetics/CGP/cosmic/), which lists NRAS mutation frequency at approximately 3% in colon cancer.
Our resource of a population-based sample of colorectal cancer (relatively unbiased samples set compared with retrospective or single-hospital-based samples) derived from 2 prospective cohorts has enabled us to precisely estimate the frequency of specific molecular events (such as KRAS,BRAF,PIK3CA mutations, CIMP) and to correlate mutations with clinical and pathologic features of colon cancer. We detected NRAS mutations in only 5 of 225 colon cancers using Pyrosequencing (Fig. 1) . On account of the low frequency, NRAS mutation was not significantly associated with any clinical or pathologic features or with patient survival. Nevertheless, there was a trend toward NRAS mutations in left-sided MSS tumors that arise in women.
Mutational activation of RAS through a point mutation at codon 12, 13, or 61 is well characterized as a marker for progression of normal or benign cells toward malignancy. 47, 48 Mutant RAS oncoproteins have decreased GTPase activity, essentially locking them into an activated state, and GTP-bound RAS transmits strong downstream signals that alter normal cellular functions. 49 Nevertheless, different cancers select for mutations in different RAS family members, suggesting that the family members exhibit cell type-specific expression patterns or functions. NRAS is, perhaps, best characterized in leukemia and melanoma, in which mutations are relatively common; NRAS mutations occur in 30% of melanomas and are mutually exclusive with mutations in BRAF, suggesting that these 2 events may be functionally equivalent. Unlike colon cancers, KRAS mutations are rare in melanomas.
Little is known regarding the impact of NRAS mutation in colorectal cancer. Some studies have shown that NRAS mutations seem to arise at a later stage in the development of malignancy, unlike KRAS mutations, which arise early. 46, 50 Recent studies using mouse models have shown clear phenotypic differences between mutant KRAS and NRAS in colon cancer. 51 Activated KRAS has a unique ability to promote tumor proliferation and to suppress differentiation, whereas activated NRAS suppressed apoptosis in a developing tumor. These data suggest that KRAS and NRAS mutations arise in response to unique selective pressures. KRAS mutations have recently been shown to arise under conditions of low glucose availability. 52 Data from animal studies suggest that NRAS mutations might arise under conditions of chronic apoptotic stress.
Although the results of our study do not reach statistical significance, the trends in the data may provide an insight into NRAS-mutant colorectal cancers. For example, our data indicate that NRAS mutations are found in left-sided MSS cancers. The mutational pattern is similar to that of KRAS, but entirely distinct from BRAF, which is mutated predominantly in right-sided CIMP-high cancers. 5, 18 Thus, whereas NRAS and BRAF may play a similar role in melanoma progression, they seem to play distinct roles in colon cancer progression.
In conclusion, our cohort study shows that the frequency of NRAS-activating mutations in colorectal cancers is low. Additional studies are needed to elucidate the mechanisms underlying the oncogenic properties of the RAS oncogenes in colorectal cancers.
